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Background: alphaB-crystallin is a small heat shock protein that has recently been characterized as an oncoprotein
correlating with the basal core phenotype and with negative prognostic factors in breast carcinomas. The purpose
of this study was to evaluate alphaB-crystallin with respect to clinicopathological parameters and the outcome of
patients with operable high-risk breast cancer.
Methods: A total of 940 tumors were examined, derived from an equal number of patients who had participated
in two randomized clinical trials (paclitaxel-containing regimen in 793 cases). Immunohistochemistry for ER, PgR,
HER2, Ki67, CK5, CK14, CK17, EGFR, alphaB-crystallin, BRCA1 and p53 was performed. BRCA1 mutation data were
available in 89 cases.
Results: alphaΒ-crystallin was expressed in 170 cases (18.1%) and more frequently in triple-negative breast carcinomas
(TNBC) (45% vs. 14.5% non-TNBC, p < 0.001). alphaB-crystallin protein expression was significantly associated with high
Ki67 (Pearson chi-square test, p < 0.001), p53 (p = 0.002) and basal cytokeratin protein expression (p < 0.001), BRCA1
mutations (p = 0.045) and negative ER (p < 0.001) and PgR (p < 0.001). Its overexpression, defined as >30% positive
neoplastic cells, was associated with adverse overall survival (Wald’s p = 0.046). However, alphaB-crystallin was not an
independent prognostic factor upon multivariate analysis. No interaction between taxane-based therapy and aΒ-crystallin
expression was observed.
Conclusions: In operable high-risk breast cancer, alphaB-crystallin protein expression is associated with poor prognostic
features indicating aggressive tumor behavior, but it does not seem to have an independent impact on patient survival
or to interfere with taxane-based therapy.
Trial registrations: ACTRN12611000506998 (HE10/97 trial) and ACTRN12609001036202 (HE10/00 trial).
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Small heat shock proteins (sHsps) are molecular chaper-
ones and are expressed in response to a wide variety of
unfavorable physiological and environmental conditions,
playing a cytoprotective role. Their importance is reflected
by the conservation of the a-crystallin structure from bac-
teria to humans [1]. alphaB-crystallin is a member of this
sHsps family, found primarily in the lens of the eye in
addition to various non-lenticular tissues [2-5]. This pro-
tein enhances survival in response to cellular stress by
inhibiting protein aggregation, reducing intracellular re-
active oxygen species levels [6] and inhibiting pro-
grammed cell death [7]. Inhibition of apoptosis is achieved
by disrupting the proteolytic activation of caspase-3 [8,9]
and by preventing translocation of Bcl-2 family members
to the mitochondria [10]. Up to date, the underlying mo-
lecular mechanisms that engender alphaB-crystallin over-
expression are poorly understood, although its prognostic
value in cancer is now becoming more obvious [7,11].
Proteomic studies suggest that alphaB-crystallin may
contribute in cancer development [12]. alphaB-crystallin
has been found in malignant diseases, such as gliomas,
prostate carcinomas, renal cell carcinomas and breast
carcinomas [13-15], while its expression has been associ-
ated with poor clinical outcome in breast, hepatocellular
and head and neck carcinomas [7,11,16,17]. Several
studies have suggested that alphaB-crystallin expression
is correlated with high histological grade, metastatic po-
tential, poor clinical outcome and chemotherapy resist-
ance in breast carcinomas [7,16,18]. Moreover, it is more
commonly expressed in basal-like breast carcinomas
(BLBC) and it is thought to contribute to their aggres-
sive phenotype [19].
BLBC has emerged as a distinct breast cancer subtype
by gene profiling studies [20,21] and is associated with
short overall and disease-free survival. BLBC express
proteins characteristic of basal epithelial cells, including
basal cytokeratins (CK5/6 and/or CK14 and/or CK17)
and commonly other markers such as p53, p-cadherin,
alphaB-crystallin, vimentin and EGFR [21-27]. The ex-
pression of basal markers identifies a distinct subgroup of
triple-negative breast cancer (TNBC), representing almost
75% of cases [23]. Moreover, there are several studies
that suggest a link between BLBC and BRCA1 muta-
tional status [25,26,28].
The limited data on alphaB-crystallin in breast cancer
suggest that there is a pathogenic link between alphaB-
crystallin expression and BLBC [19,29]. In this study, the
expression of alphaB-crystallin was evaluated in a large
cohort of two randomized trials in order to evaluate pos-
sible associations with conventional clinicopathological
characteristics, including established prognostic factors,
such as histological grade, molecular subtypes and meta-




The HE10/97 trial [30] was a randomized phase III trial
(ACTRN12611000506998) in patients with high-risk node-
negative or intermediate/high-risk node-positive operable
breast cancer, comparing four cycles of epirubicin (E)
followed by four cycles of intensified CMF (E-CMF) with
three cycles of E, followed by three cycles of paclitaxel (T,
Taxol®, Bristol Myers-Squibb, Princeton, NJ) followed by
three cycles of intensified CMF (E-T-CMF). All cycles
were given every two weeks with G-CSF support. Dose in-
tensity of all drugs in both treatment arms was identical,
but cumulative doses and duration of chemotherapy
period differed. Totally, 595 eligible patients entered the
study in a period of 3.5 years (1997–2000).
The HE10/00 trial [31,32] was a randomized phase III
trial (ACTRN12609001036202) in which patients were
treated with E-T-CMF (exactly as in the HE10/97 trial)
or with four cycles of epirubicin/paclitaxel (ET) combin-
ation (given on the same day) every three weeks fol-
lowed by three cycles of intensified CMF every two
weeks (ET-CMF). By study design, the cumulative doses
and the chemotherapy duration were identical in the
two arms but dose intensity of epirubicin and paclitaxel
was double in the E-T-CMF arm. A total of 1086 eligible
patients with node-positive operable breast cancer were
accrued in a period of 5 years (2000–2005).
Treatment schedules for the two studies, baseline
characteristics and clinical outcomes of both trials have
already been described in detail [30-33]. Clinical proto-
cols were approved by local regulatory authorities, while
the present translational research protocol was approved
by the Bioethics Committee of the Aristotle University
of Thessaloniki, School of Medicine, under the general
title “Molecular investigation of the predictive and/or
prognostic role of important signal transduction path-
ways in breast cancer” (A7150/18-3-2008). All patients
signed a study-specific written informed consent before
randomization, which in addition to providing consent
for the trial allowed the use of their biological material
for future research purposes.
In total, 271 patients from the HE10/97 trial and 669
from the HE10/00 trial were included in this study,
based on tissue availability. Primary tumor diameter, ax-
illary nodal status and tumor grade were obtained from
the pathology report in each case.
TMA construction
Formalin-fixed paraffin-embedded (FFPE) tissue samples
from patient tumors (paraffin blocks) were collected retro-
spectively in the first trial (HE10/97) and prospectively in
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on tissue microarrays (TMAs). Representative hematoxylin-
eosin stained sections from the tissue blocks were re-
viewed by two experienced in breast cancer pathologists
and the most representative tumor areas were marked for
the construction of ΤΜΑ blocks with a manual arrayer
(Model I, Beecher Instruments, San Prairie, WI). Each
tumor was represented by 2 tissue cores, 1.5 mm in diam-
eter, which were obtained from different and most repre-
sentative areas of primary invasive or in some cases from
synchronous axillary lymph node metastases and re-
embedded in recipient paraffin blocks. TMAs also
contained control cores from different tumors and non-
neoplastic tissues [32]. In total, 51 TMAs were created.
Cases not represented, damaged or inadequate on the
TMA sections were re-cut from the original blocks, where
tissue material was still available.
Immunohistochemistry (IHC) for breast cancer subtyping
IHC for ER (clone 6 F11, Leica Biosystems, Newcastle
Upon Tyne, UK), PgR (clone 1A6, Leica Biosystems),
HER2 (pl, code A0485, Dako, Glostrup, DK), Ki67 (clone
MIB1, Dako), CK5 (clone XM26, Leica Biosystems), CK14
(clone LL002, Leica Biosystems), CK17 (E31, Leica Biosys-
tems) and EGFR (clone 31G7, Invitrogen, Carlsbad, CA)
was performed on serial 2 micron thick sections, using the
Bond Max and Bond III autostainers (Leica Microsystems,
Wetzlar, Germany), as previously described [34]. IHC was
performed centrally at the Laboratory of Molecular On-
cology of the Hellenic Foundation for Cancer Research,
Aristotle University of Thessaloniki School of Medicine.
Vimentin (clone V9, Dako) and cytokeratin 8/18 (clone
5D3, Leica Biosystems) were used as immunoreactivityTable 1 Criteria of immunohistochemical evaluation
Protein Scoring system Cut-off Staining pattern
ER H-Score ≥1% N
PgR H-Score ≥1% N
HER2 0-3 >10% M
p53 SQ >10% N
Ki67 SQ ≥14% N
EGFR 0-3 >1% M
CK5 SQ any C
CK14 SQ any C
CK17 SQ any C
CK8/18 SQ any C
Vimentin SQ any C
alphaB-crystallin Neg, W, S >30 C
BRCA1 H-Score >100 N
H-Score, histoscore; N, nuclear; M, membranous; C, cytoplasmic; SQ, semi-
quantitative; Neg, negative; W, weakly positive; S, strongly positive.controls and for the identification of tumor cells. Tissue
samples negative with the above two antibodies were ex-
cluded from the study. The evaluation of all IHC sections
was done by experienced breast cancer pathologists,Mixed 72 (7.7)
Other 44 (4.7)













Missing data 31 (3.3)
N, number; E, epirubicin; T, paxlitaxel; C, cyclophosphamide; M, methotrexate;
F, 5-FU; MRM, modified radical mastectomy; HT, hormonal therapy; RT,
radiotherapy.
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data.
All tumors included in this study were classified based
on ER, PgR, HER2, Ki67, CK5 and EGFR, as Luminal A
(ER-positive and/or PgR-positive, HER2-negative and
Ki67low), Luminal B (ER-positive and/or PgR-positive,
HER2-negative and Ki67high), luminal-HER2 (ER-positive
and/or PgR-positive and HER2-positive), HER2-enriched
(ER-negative, PgR-negative, HER2-positive) and TNBC
(ER-negative, PgR-negative, HER2-negative). Tumors were
classified as Ki67high when ≥14% of neoplastic cells were
positive [35]. TNBC of the basal core phenotype (BCP)
were also distinguished as CK5-positive and/or EGFR-
positive.
IHC for alphaB-crystallin, BRCA1 and p53 markers
The IHC method was performed using the Bond Max
and Bond III autostainers (Leica Microsystems). The
Mouse IgG1 monoclonal antibody, clone 1B6.1-3G4
(Stressgen Biotechnologies, San Diego, CA) was used for
the detection of full-length alphaB-crystallin (1:200 dilu-
tion, 1 h incubation at room temperature). The MS110
antibody from Merck KGaA (Darmstadt, Germany) was
used for BRCA1 detection (1:150 dilution, for 20 min),
while p53 protein was detected with the DO-7 clone
(Dako) at dilution 1:100, for 20 min. The antigen–anti-
body complex was visualized using DAB as a chromogen.Figure 1 alphaB-crystallin immunohistochemical detection in cancero
of neoplastic cells is shown in A, whereas neoplastic cells are negative in B
Nerve fibers and adipose tissues are also immunoreactive. (A: ×40, B-D: ×1Slides were counterstained with Mayer’s hematoxylin
for 10 min (Leica), washed in water, dehydrated and
mounted.
IHC evaluation
ER, PgR, HER2, Ki67 and EGFR protein expression was
evaluated according to the established or proposed cri-
teria [35-38]. CK5, CK14 and CK17 expression was con-
sidered as negative (absence of staining) or positive (any
cytoplasmic staining of tumor cells) [34]. For alphaB-
crystallin the percentage of positive tumor cells and the
intensity (mild, moderate, strong) were recorded in every
case. The distribution of continuous positivity values re-
vealed a natural cut-off at 30%. Tumors were considered
negative, when no specific cytoplasmic staining was ob-
served, weakly positive (<30% positive neoplastic cells)
and strongly positive (≥30% positive neoplastic cells). In
the latter category staining intensity was predominantly
strong; therefore, intensity was not included in the statis-
tical analysis. The above staining pattern was in accord-
ance with Moyano’s previous report [7], who used a cutoff
of ≥30% to evaluate low and high alphaB-crystallin ex-
pressing tumors. BRCA1 staining was evaluated by using
the histological score (H-score) at a positivity cut-off of >
100 [39]. For p53, ≥10% nuclear staining of invasive cancer
cells was considered positive [40]. IHC positivity criteria for
all antibodies are shown in Table 1.us and non-cancerous tissues. Strong cytoplasmic immunoreactivity
-D. In normal breast tissue only myoepithelial cells are positive (B).
00).
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FISH using the ZytoLightH SPEC HER2/TOP2A/CEN17
triple color probe (ZytoVision, Bremerhaven, Germany),
as previously described [41].BRCA mutations
DNA for BRCA screening was available for 127 of the
940 patients included in the present analysis. Seventy-
nine patients were screened for BRCA1 only, 3 patientsTable 3 Distribution of the examined markers
N (%)
ER (n = 938)
Negative 245 (26.1)
Positive 693 (73.9)
PgR (n = 940)
Negative 301 (32.0)
Positive 639 (68.0)
Ki67 (n = 934)
Low 299 (32.0)
High 635 (68.0)
alphaB-crystallin (n = 940)
Negative 770 (81.9)
Weakly positive 99 (10.5)
Strongly positive 71 (7.6)
BRCA1 (n = 928)
Negative 863 (93.0)
Positive 65 (7.0)
BRCA1 (n = 86)
WT 78 (90.7)
Mutated 8 (9.3)
p53 (n = 918)
Negative 445 (48.5)
Positive 473 (51.5)
EGFR (n = 928)
Negative 777 (83.7)
Positive 151 (16.3)
CK5 (n = 923)
Negative 802 (86.9)
Positive 121 (13.1)
CK14 (n = 925)
Negative 894 (96.6)
Positive 31 (3.4)
CK17 (n = 909)
Negative 884 (97.2)
Positive 25 (2.8)
WT, wild-type.were screened for BRCA2 only and 7 patients were
screened in both genes. Thirty-eight patients were not
screened due to low quality of the DNA sample. Genomic
DNA was isolated from peripheral blood lymphocytes fol-
lowing the salt extraction procedure [42]. The quantity
and quality of the DNA samples were determined by UV
absorbance using a Nanodrop™ 1000 (Thermo Fisher
Scientific, MA) and agarose gel electrophoresis. BRCA1
and BRCA2 were amplified using intronic primer pairs










N (%) N (%) N (%)
Randomization arm 0.556
E-T-CMF 367 (47.7) 55 (55.6) 32 (45.1)
E-CMF 126 (16.4) 8 (8.1) 13 (18.3)
ET-CMF 277 (36.0) 36 (36.4) 26 (36.6)
Age 0.058
<50 301 (39.1) 47 (47.5) 33 (46.5)
≥50 469 (60.9) 52 (52.5) 38 (53.5)
Menopausal status 0.402
Premenopausal 351 (45.6) 51 (51.5) 33 (46.5)
Postmenopausal 419 (54.4) 48 (48.5) 38 (53.5)
Type of surgery <0.001
MRM 548 (71.2) 53 (53.5) 43 (60.6)
Breast conserving 222 (28.8) 46 (46.5) 28 (39.4)
Tumor size (cm) 0.937
≤2 232 (30.1) 35 (35.4) 21 (29.6)
2.1-5 435 (56.5) 55 (55.6) 40 (56.3)
>5
Histological type 0.084
Ductal 586 (76.1) 80 (80.8) 61 (85.9)
Lobular 89 (11.6) 6 (6.1) 2 (2.8)
Mixed 59 (7.7) 10 (10.1) 3 (4.2)
Other 36 (4.7) 3 (3.0) 5 (7.0)
Number of positive nodes 0.957
0-3 298 (38.7) 36 (36.4) 29 (40.8)
≥4 472 (61.3) 63 (63.6) 42 (59.2)
Histological grade <0.001
I-II 406 (52.7) 40 (40.4) 24 (33.8)
III-Undifferentiated 364 (47.3) 59 (59.6) 47 (66.2)
N, number; E, epirubicin; T, paxlitaxel; C, cyclophosphamide; M, methotrexate;
F, 5-FU; MRM, modified radical mastectomy.
Significant p-values are shown in bold.
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genomic rearrangements involving exons 20, 23 and 24
[43]. PCR amplifications were performed in a Veriti 96-
Well Thermal Cycler and the PCR products were directly
sequenced using the v.3.1 BigDye Terminator Cycle Se-
quencing kit on an 3130XL Genetic Analyzer (all three
from Applied Biosystems, Foster City, CA), according to
the manufacturer’s instructions. In some cases of high-risk
families, genomic DNA was also examined by MLPA
analysis (MRC-Holland). Sequence variations, except well-
known polymorphisms, were confirmed in an independ-
ent blood sample by sequencing both forward and reverse
directions. All nucleotide numbers refer to the wild-type
genomic DNA sequence of BRCA1 NG_005905.2 and
BRCA2 NG_012772.1, as reported in RefSeqGene records.
Primer sequences and protocols are available upon
request.Statistical analysis
Categorical data are displayed as frequencies and corre-
sponding percentages, while continuous data by median
and range. Comparisons of categorical data between
groups were performed by Fisher’s exact or Pearson chi-
square tests. For continuous data, the assumptions for
performing parametric tests were not fulfilled (the data
were not normally distributed); therefore the non-
parametric Kruskal-Wallis test was used. For numerical
ordinal data, the Jonckheere-Terpstra trend test (JT test)
was performed. Disease-free survival (DFS) was mea-
sured from the date of randomization until tumor recur-
rence, secondary neoplasm or death from any cause.Table 5 Distribution of examined markers according to subty
Luminal A Luminal B Lumin
N (%) N (%) N
alphaB-crystallin
Negative 213 (93.4) 299 (80.6) 109
Weakly positive 8 (3.5) 40 (10.8) 16
Strongly positive 7 (3.1) 32 (8.6) 5
BRCA1
Negative 206 (92.0) 334 (91.0) 125
Positive 18 (8.0) 33 (9.0) 3
BRCA1
WT 19 (90.5) 27 (100.0) 11
Mutated 2 (9.5) 0
p53
Negative 148 (67.3) 154 (42.1) 56
Positive 72 (32.7) 212 (57.9) 72
N, number; TNBC, triple-negative breast cancer; BCP, basal core phenotype; WT, wilOverall survival (OS) was measured from the date of
randomization until death from any cause. Surviving pa-
tients were censored at the date of last contact. Time-to-
event distributions were presented using Kaplan-Meier
curves and compared using the log-rank test.
Univariate Cox regression analyses were performed for
OS and DFS, to assess the prognostic or predictive sig-
nificance in paclitaxel treatment of the examined
biomarkers. A backward selection procedure with a re-
moval criterion of p > 0.10 was performed in the multi-
variate Cox regression analysis in order to identify
significant factors among the following: randomization
group (ET-CMF, E-CMF, vs. E-C-MF), involved axillary
lymph nodes (≥4 vs. 0–3), tumor grade (III-Undifferenti-
ated vs. I-II), tumor size (>5 cm, 2–5 cm vs. ≤2 cm), type
of surgery (breast conserving surgery vs. modified radical
mastectomy, ΜRΜ), histological type (ductal vs. other)
and adjuvant hormonal therapy (yes, missing vs. no).
The examined markers were included in the final model
using the categorization: alphaB-crystallin (strong posi-
tive, weak positive vs. negative), p53 (positive vs. nega-
tive) and BRCA1 (positive vs. negative).
Results of this study were presented according to re-
ported recommendations for tumor marker prognostic
studies [44]. The design of the study is prospective-
retrospective, as previously described by Simon et al.
[45]. All statistical tests were two sided and p < 0.05 was
considered statistically significant. No adjustments for
multiple tests are reported. The statistical analysis was
conducted using the following statistical software: SPSS
for Windows (version 15.0, IBM Corporation, NY) and
SAS (version 9.3, SAS Institute Inc., Cary, NC).pes
al-HER2 HER2-enriched TNBC BCP
(%) N (%) N (%) N (%)
(83.8) 88 (88.0) 61 (55.0) 41 (48.2)
(12.3) 11 (11.0) 24 (21.6) 19 (22.4)
(3.8) 1 (1.0) 26 (23.4) 25 (29.4)
(97.7) 95 (95.0) 103 (94.5) 79 (92.9)
(2.3) 5 (5.0) 6 (5.5) 6 (7.1)
(100.0) 10 (100.0) 11 (64.7) 9 (60.0)
0 0 6 (35.3) 6 (40.0)
(43.8) 41 (42.3) 46 (43.0) 32 (38.6)
(56.3) 56 (57.7) 61 (57.0) 51 (61.4)
d-type.
Table 6 Association of alphaB-crystallin protein expression
with all examined markers
alphaB-crystallin








ER (n = 938) <0.001
Negative 176 (71.8) 38 (15.5) 31 (12.7)
Positive 592 (85.4) 61 (8.8) 40 (5.8)
PgR (n = 940) <0.001
Negative 227 (75.4) 38 (12.6) 36 (12.0)
Positive 543 (85.0) 61 (9.5) 35 (5.5)
Ki67 (n = 934) <0.001
Low 267 (89.3) 17 (5.7) 15 (5.0)
High 499 (78.6) 81 (12.8) 55 (8.6)
BRCA1 (n = 928) 0.676
Negative 707 (81.9) 91 (10.6) 65 (7.5)
Positive 52 (80.0) 7 (10.8) 6 (9.2)
BRCA1 (n = 86) 0.045
WT 61 (78.2) 11 (14.1) 6 (7.7)
Mutated 4 (50.0) 1 (12.5) 3 (37.5)
p53 (n = 918) 0.002
Negative 384 (86.3) 32 (7.2) 29 (6.5)
Positive 370 (78.2) 66 (14.0) 37 (7.8)
EGFR (n = 928) <0.001
Negative 671 (86.3) 65 (8.4) 41 (5.3)
Positive 91 (60.3) 32 (21.2) 28 (18.5)
CK5 (n = 923) <0.001
Negative 694 (86.5) 67 (8.4) 41 (5.1)
Positive 63 (52.1) 31 (25.6) 27 (22.3)
CK14 (n = 925) <0.001
Negative 750 (83.9) 88 (9.8) 56 (6.3)
Positive 9 (29.0) 10 (32.3) 12 (38.7)
CK17 (n = 909) <0.001
Negative 742 (83.9) 87 (9.9) 55 (6.2)
Positive 5 (20.0) 9 (36.0) 11 (44)
WT, wild-type.
Significant p-values are shown in bold.
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Clinicopathological characteristics of patients and tumor
subtyping
A total of 940 patients with available FFPE tumor tissue
blocks and successful assessment of alphaB-crystallin
were included in the analysis. Selected patient and
tumor characteristics are presented in Table 2. The ma-
jority of the patients were postmenopausal (54%) and
underwent modified radical mastectomy (69%). The
most common histological type was infiltrative ductal
carcinoma, which accounted for 77.3% of the cases. Half
of the tumors were of high histological grade and about
70% measured >2 cm. Almost two thirds of patients had
4 or more metastatic lymph nodes at the time of diagno-
sis. By using IHC for molecular subtyping [32], 24.3% of
the tumors were classified as Luminal A, 39.5% as Luminal
B, 13.8% as Luminal-HER2, 10.6% as HER2-enriched and
11.8% as TNBC.
alphaB-crystallin detection by IHC
The protein was generally localized in the cytoplasm
(Figure 1A), whereas membranous positivity was ob-
served sparsely and it was mainly focal and incomplete.
Few cases (n = 46) exhibited nuclear positivity in <5% of
the nuclei that was usually not accompanied by cytoplas-
mic positivity. The nuclear presence of alphaB-crystallin
has been previously described [2,46], suggesting a possible
role in splicing or in protection of the splicing machinery
[46]. Subsequently, tumors were considered as alphaB-
crystallin positive based on the cytoplasmic staining of
malignant cells. Of note, variable alphaB-crystallin positiv-
ity scores were obtained from the examined cores for the
same tumor, ranging from negative to strongly positive.
Regarding the non-cancerous breast tissue included in
histospots, cytoplasmic alphaB-crystallin expression was
observed only in myoepithelial cells (Figure 1B). Gener-
ally, expression of the protein was not detected in epi-
thelial cells of lobular units or ductal structures. Stromal
breast cells were globally negative. Wherever nerves, adi-
pose tissue, vessels (Figure 1C and 1D) and muscle cells
could be evaluated, these were consistently positive.
Association of alphaΒ-crystallin with clinopathological
features and other markers
The distribution of the examined markers is given in
Table 3. The majority of cases were ER- and PgR-
positive (74% and 68%, respectively) with high Ki67
(68%). alphaΒ-crystallin was expressed in 170 of the 940
breast carcinomas (18.1%). In detail, 770 tumors (81.9%)
were negative, 99 (10.5%) were weakly positive and 71
(7.6%) were strongly positive (Table 3). Associations of
alphaB-crystallin with clinicopathological parameters are
presented in Table 4. High histological grade was more
frequent among tumors expressing strong alphaB-crystallin than among tumors with weak or absent stain-
ing (p < 0.001). alphaB-crystallin protein expression was
not associated with patients’ age, tumor size, histological
type or lymph node involvement. The incidence for
alphaB-crystallin positive cases (weak or strong expres-
sion in the tumors) was by far higher in TNBC (45%)
than in non-TNBC (14.5%) patients, while most Luminal
A tumors were negative for alphaB-crystallin expression
(93.4%, Table 5). Out of the 85 BCP tumors, 44 expressed
alphaB-crystallin (52%).
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often detected in ER- and PgR-negative tumors, whereas
there was a positive association with Ki67, p53, CK5,
CK14 and CK17 (Table 6). A strong, positive association
was noticed between alphaB-crystallin expression and
Ki67, with 81.3% of the cases with positive expression of
the former having high expression of the latter. In
addition, BRCA1 mutations were more frequent (p =
0.045) in tumors with strong alphaB-crystallin protein
expression compared to tumors with weak or negative
expression (33.3% vs. 8.3% vs. 6.2%, respectively). BRCA1
mutation status was not related to BRCA protein expres-
sion (p = 0.40). However, it has to be kept in mind, that
DNA for BRCA1 screening was available for only 86 of
the 940 patients included in the present analysis and that
this subgroup of patients showed significant differences
compared to the overall cohort regarding age, menopausal
status, type of surgery, involved axillary lymph nodes and
randomization group.
Survival analysis
After a median follow-up of 105 months (0.1-166.7 months),
5 and 10-year DFS was 73.7% and 60.7%, respectively.
Similarly 5 and 10-year OS was 86.4% and 70.8% respect-
ively. In univariate Cox regression analysis (Table 7),
BRCA1 mutation status and alphaB-crystallin, BRCA1 and











alphaB-crystallin (strongly positive vs. weakly positive/negative)
p53 protein expression
HR, hazard ratio; CI, confidence interval.prognostic and predictive value. alphaB-crystallin (3 scale
categoric variable) was not associated with either DFS or
OS (Table 7 and Figure 2), however, a statistically signifi-
cant association with OS (but not with DFS) was revealed,
when strongly positive tumors were compared against
negative and weakly positive tumors in a binary mode
(hazard ratio [HR] = 1.52, 95% confidence interval [CI]:
1.01-2.30, Wald’s p = 0.046). Concerning BRCA1 protein
expression and BRCA1 mutational status (Table 7), no sig-
nificant associations were found with for DFS or OS (Wald’s
p-values >0.05 for all cases). Positive p53 tumors exhibited
a trend for shorter DFS (HR = 1.21, 95% CI: 0.97-1.50,
Wald’s p = 0.088) and shorter OS (HR = 1.24, 95% CI: 0.98-
1.65, Wald’s p = 0.066) compared to negative p53 tumors.
There were no significant interactions of alphaB-
crystallin with paclitaxel treatment (Wald’s p = 0.72 and
p = 0.75 for DFS and OS, respectively). No significant in-
teractions were found either for BRCA1 and p53 protein
expression or BRCA1 mutational status with paclitaxel
treatment (Wald test for interaction, all p-values >0.05)
(Table 8).
In multivariate Cox regression analysis, alphaB-crystallin,
BRCA1 and p53 protein expression were not prognostic
for DFS and OS. Among clinical characteristics, tumor
size of more than 5 cm and ≥4 positive axillary nodes were
independent prognostic factors and were associated with
poor DFS and OS (Figure 3).arkers in terms of DFS and OS
DFS
HR 95% CI Wald’s p
Category vs. the reference
Mutated 1.68 (0.59-4.80) 0.33
Positive 0.99 (0.65-1.51) 0.95
0.79
Weakly positive 1.02 (0.72-1.45) 0.91
Strongly positive 1.14 (0.77-1.69) 0.50
Strongly positive 1.14 (0.77-1.68) 0.51
Positive 1.21 (0.97-1.50) 0.088
OS
HR 95% CI Wald’s p
Category vs. the reference
Mutated 1.75 (0.52-5.86) 0.36
Positive 0.95 (0.57-1.58) 0.86
0.14
Weakly positive 0.98 (0.65-1.49) 0.94
Strongly positive 1.52 (1.00-2.31) 0.050
Strongly positive 1.52 (1.01-2.30) 0.046
Positive 1.24 (0.98-1.65) 0.066
Figure 2 DFS (left) and OS (right) according to alphaB-crystallin protein expression.
Koletsa et al. BMC Clinical Pathology 2014, 14:28 Page 9 of 13
http://www.biomedcentral.com/1472-6890/14/28Discussion
In this study, including a large cohort of breast cancer
cases, it is demonstrated that alphaB-crystallin is ex-
pressed in a low percentage of breast carcinomas
(18,1%), which drops to 7.6% when the Moyano-
suggested cut off for strong positivity (>30% positive
cells) is applied. These findings are within the reported
range of alphaB-crystallin protein expression (10 and
17%) [7,18,19]. However, two studies reported high rates
of alphaB-crystallin expression with the same antibody
(64.6 and 88%) [11,16]. Differences in TMA construction
and IHC evaluation may account for this discrepancy. InTable 8 Interaction of all examined markers with paclitaxel tr
HR
alphaB-crystallin * Treatment
alphaB-crystallin neg vs. pos in non-paclitaxel treated 1.21
alphaB-crystallin neg vs. pos in paclitaxel treated 0.81
Non-paclitaxel treated vs. paclitaxel treated in alphaB-crystallin neg 1.23
Non-paclitaxel treated vs. paclitaxel treated in alphaB-crystallin pos 0.82
BRCA1 * Treatment
BRCA1 neg vs. pos in non-paclitaxel treated 1.43
BRCA1 neg vs. pos in paclitaxel treated 0.96
Non-paclitaxel treated vs. paclitaxel treated in BRCA1 neg 1.19
Non-paclitaxel treated vs. paclitaxel treated in BRCA1 pos 0.79
BRCA1 * Treatment
BRCA1 WT vs. mut in non-paclitaxel treated1 .
BRCA1 WT vs. mut in paclitaxel treated 0.61
Non-paclitaxel treated vs. paclitaxel treated in BRCA1 WT 0.76
Non-paclitaxel treated vs. paclitaxel treated in BRCA1 mut1 .
p53 * Treatment
p53 neg vs. pos in non-paclitaxel treated 1.06
p53 neg vs. pos in paclitaxel treated 0.80
Non-paclitaxel treated vs. paclitaxel treated in p53 neg 1.36
Non-paclitaxel treated vs. paclitaxel treated in p53 pos 1.02
*: interaction; 1: There were no patients with BRCA1 mutations in the non-paclitaxel
HR, hazard ratio; CI, confidence interval; pos, positive; neg, negative; mut, mutated;both studies, alphaB-crystallin was scored according to
the highest intensity even in a few cells regardless of
how many cells actually expressed this protein. In
addition, 81 of the 82 cases [11] were TNBC, which
often express alphaB-crystallin; a high percentage of
TNBC can also be inferred from the ER/PgR/HER2 pro-
files of the tumors examined [16].
It seems that BCP express this protein more often. As
described here, 45% (50/111) of TNBC and almost half
of BCP were alphaB-crystallin positive. Sitterding et al.
suggested that alphaB-crystallin is a sensitive and
specific marker for BCP [29]. In addition, it is alsoeatment in terms of DFS and OS
DFS OS
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basal markers, such as CK5, CK14 and CK17. Consider-
ing that alphaB-crystallin is expressed in normal myoe-
pithelial cells it can be viewed as a basal/myoepithelial
marker or as the organizer of stratified cytokeratins
through its ability to regulate the cytoskeleton organiza-
tion [47]. The fact that almost half of BCP, as shown in
this study, express alphaB-crystallin raises the question
why the remaining BCP cases fail to express this protein.
This finding could be due to immunostain heterogeneity
or BCP heterogeneity as they represent a heterogeneous
group. The effort of identifying new molecular markers
to subdivide BCP subtypes is still ongoing [22,48]. On
the other hand, the heterogeneous pattern of alphaB-
crystallin expression throughout the tumor area, as ob-
served in our study, prompts for caution when using
TMAs for the assessment of tumor immunoreactivity of
this marker.
The oncogenic role of alphaB-crystallin has been dem-
onstrated in two human mammary epithelial cell lines
and in experimental mice models, where it results in the
development of invasive mammary carcinomas [7]. Re-
cently, it has been suggested that alphaB-crystallin pro-
motes tumor progression by enhancing endothelial cell
survival, resulting in efficient tumor vascularizationFigure 3 Multivariate Cox regression analysis for DFS and OS present[49,50]. There are several studies that introduce sHsps
and especially Hsp27 and alphaB-crystallin as contribu-
tors to the epithelial-mesenchymal transition (EMT)
process. Both proteins interact with the cytoskeleton and
regulate its dynamic status by inducing mesenchymal-
like spindle cells; thus, they may promote cancer cell
invasion and metastasis [47,51]. Consequently, alphaB-
crystallin may contribute to an aggressive behavior of
tumors; this is in line with our observation that alphaB-
crystallin is more commonly found in BCP and in those
non-TNBC that have a high histological grade and pro-
liferation rate. Of note, in the current study the majority
of non-TNBC alphaB-crystallin positive cases were
Luminal B tumors, which by definition have a high Ki67
labeling index. The expression of alphaB-crystallin in a
subset of non-TNBC has been mentioned by other stud-
ies, as well [7,11,18].
BCP constitute a tumor subgroup associated with
BRCA1 mutations. Tumors of patients with BRCA1 germ-
line mutations usually display the basal core phenotype
[52,53]. In this study we found that alphaB-crystallin is as-
sociated with BCP and BRCA1 mutational status but not
with BRCA1 protein expression. Moreover, no significant
association was found between mutational status and pro-
tein expression. Despite the small sample size (n = 8) ofed by forest plots.
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view that IHC does not reliably reflect BRCA1 gene status
and cannot be used for assessing the impact of BRCA1
protein expression on prognosis [52,54-56]. We also found
a strong association between alphaB-crystallin and p53 ex-
pression, which is again in line with BCP – BRCA1 mu-
tant tumors. alphaB-crystallin overexpression prevents
apoptosis, through the interaction of the p53 down regu-
lated genes, such as bax or pro-caspase3 [57,58]. Recently,
it was shown that alphaB-crystallin binds to p53 to se-
quester its translocation to the mitochondria during
hydrogen peroxide induced apoptosis [58]. Hence, like
other Hsps, alphaB-crystallin interacts with p53 and mod-
ulates its function. On the other hand, it is believed that
p53 is involved in the regulation of Hsps in cancer and
p53 mutations result in an increase of Hsp transcripts
[59,60]. Our IHC findings further support these interac-
tions, specifically between the alphaB-crystallin and p53
proteins.
alphaB-crystallin expression has been associated with
poor clinical outcome in breast [7,11], head and neck
[17] and hepatocellular carcinoma [61]. Moyano et al.
found that this biomarker predicts for shorter disease-
specific survival, independent of other prognostic
markers. By contrast, Chelouche-Lev et al. reported that
this sHsp inadequately predicts patient outcome [16],
despite the fact that it is strongly associated with the
presence of lymph node metastasis. Herein we observed
a statistically significant association between strong pro-
tein expression of alphaB-crystallin (as determined by
Moyano) and overall survival. This may indicate that
alphaB-crystallin overexpression actually contributes to
tumor aggressiveness that has a negative impact on pa-
tients’ survival. It should be noted that only 7.6% (71/
940) of the patients were strongly positive, when using
the above cut-off for overexpression, which might have
produced biased results. Nevertheless, the present multi-
variate analysis data indicated that alphaB-crystallin
might not be considered to be an independent prognos-
tic marker in breast cancer.
Regarding to its predictive role, increased expression
of alphaB-crystallin has been associated with acquired
resistance to cisplatin, etoposide and fotemustine [62].
Ivanov et al. described that there is an association be-
tween alphaB-crystallin expression and resistance to
neoadjuvant chemotherapy in breast cancer, suggesting
its possible role in the identification of a chemoresistant
subset of TNBC [18]. In this particular study alphaB-
crystallin was not shown to be a predictive marker for
response to paclitaxel therapy. Similarly, in the present
study, we did not find any interaction between alphaB-
crystallin and taxane-containing regimens. Although this
is a negative result, to our knowledge, this is the first re-
port attempting to establish an interaction betweentaxane-based therapies and alphaB-crystallin protein
expression.
Conclusions
alphaB-crystallin cannot be considered to be a marker
for BCP but a protein expressed in carcinomas with ag-
gressive biologic nature that are characterized by high
labeling index (Ki67/mib1), triple-negative phenotype,
basal protein expression, p53 overexpression and high
histological grade. However, alphaB-crystallin does not
seem to have an independent impact on patient progno-
sis. Evidently, since results on outcome are IHC cut-off
sensitive, the applied cut-off needs further validation.
Lastly, although alphaB-crystallin protein expression was
not shown to be a predictive marker for taxane-based
therapy, to our knowledge this is the first study to evalu-
ate the association between alphaB-crystallin and
taxane-based therapy in a large cohort of patients. Fur-
ther studies are needed to evaluate this result in a bal-
anced patient population.
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